Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15–20% of breast cancers [1], leading to an increased number of HER2 dimers and hyperactivation of pathways like those of PI3K-Akt and MAPK, as shown in Figure 1 [2]. The gene discussed is ERBB2; the disease is breast carcinoma.